Mark Kankel, PhD
Co-founder & Vice President of Research
Leader in CNS, Neuromuscular, & Drug Development
Mark is a neuroscientist with deep expertise in neurodegenerative diseases. He began his career at Biogen, contributing to drug development efforts for Alzheimer’s, SMA, Parkinson’s, and ALS over a decade. He later led early-stage R&D at Apple Tree Partners (ATP). Mark earned his PhD from Washington University in St. Louis and completed postdoctoral training at Harvard Medical School. With 20+ publications and patents, Mark brings both scientific rigor and heartfelt commitment to advancing ALS research.